Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by State Street Corp

State Street Corp raised its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 119.6% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 2,190,239 shares of the company's stock after purchasing an additional 1,192,812 shares during the period. State Street Corp owned 3.24% of Perspective Therapeutics worth $29,240,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter worth $57,000. US Bancorp DE increased its position in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics in the third quarter valued at approximately $153,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Price Performance

Shares of CATX traded up $0.01 during midday trading on Friday, reaching $2.85. The stock had a trading volume of 2,862,420 shares, compared to its average volume of 883,322. The company's fifty day simple moving average is $7.79 and its two-hundred day simple moving average is $11.09. Perspective Therapeutics, Inc. has a 1-year low of $2.70 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million during the quarter. Equities analysts forecast that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CATX shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating on the stock in a research report on Monday, November 25th. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective for the company. Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.14.

Insiders Place Their Bets

In other news, CFO Jonathan Robert Hunt bought 12,829 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Heidi Henson purchased 25,975 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company's stock, valued at $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is owned by corporate insiders.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.